The patients had significantly decreased health status in all domains of SF-36—role functioning, physical functioning, vitality, mental health, and health percep-tions—when compared with age-matched control subjects (Fig 2). To determine the effect of the severity of sleep apnea on the quality of life, the indicators of disease severity, the RDI and arousal indices, and the lowest oxygen saturation during sleep were correlated with each domain of the SF-36. There were no significant correlations among any of these measures. Some patients with mild OSA reported significant impairment in their quality of life, although others with more severe OSA perceived a lesser amount of functional decline. The impact of comorbidity on SF-36 domains was examined using analysis of variance for the absence or presence of comorbidity. The presence of comorbidity significantly curtailed role functioning related to work or other daily activities as a result of physical health: 72.8 ± 11.3 with no comorbidity vs 22.7 ± 9.6 with at least one comorbidity (p = 0.003).
All patients underwent and responded to nCPAP treatment, with a reported use time of 6.0 ± 1.6 h/night. The RDI decreased from 77 ± 9 to 4 ± 6 events/h (p < 0.0001), and the arousal index decreased from 67 ± 7 to 13 ± 3 arousals/h (p < 0.001) (Fig 1). The arterial oxygen saturation during sleep increased from 79.0 ± 2.1% to 91.6 ± 0.8%, and the mean optimal nCPAP level was 9.4 ± 0.7 cm H2O.
After 8 weeks of nCPAP treatment, the patients reported a significant improvement in vitality (p = 0.0004), social functioning (p = 0.009), and mental health (p = 0.01) when compared to baseline values for each individual. There was no correlation between the severity of sleep apnea, the RDI, the lowest arterial oxygen saturation or frequency of oxygen desaturations, and the degree of improvement in quality of life measures after nCPAP treatment there canadian family pharmacy online. We used multiple regression analysis to identify the factors of age, body mass index, RDI and arousal indices, and the use of nCPAP as independent variables that could have predicted the improvement in SF-36 measures.

Figure 2. SF-36 domains before and after 8 weeks of nCPAP treatment. The third column denotes age-matched normative values. The p values are corrected for multiple comparisons using the Bonferroni adjustment.

Figure 2. SF-36 domains before and after 8 weeks of nCPAP treatment. The third column denotes age-matched normative values. The p values are corrected for multiple comparisons using the Bonferroni adjustment.